领航医药生物科技中期报告 2024-2025

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)()(Stock Code399 ) INTERIM REPORT2024/25 Contents目錄 2Corporate Information4Management Discussion and Analysis12Other Information Provided inAccordance with the Listing Rules18Condensed Consolidated Statementof Profit or Loss and OtherComprehensive Income20Condensed Consolidated Statement ofFinancial Position23Condensed Consolidated Statement ofChanges in Equity25Condensed Consolidated Statement ofCash Flows26Notes to the Condensed ConsolidatedFinancial Statements Corporate Information公司資料 BOARD OF DIRECTORSExecutive DirectorsGao Yuan XingTang RongCheng Tak Yiu Non-executive DirectorsJiang Nian(Chairman)Xiao YanWu Yanmin Independent non-executive DirectorsChen WeijunWang RongliangChen Jinzhong Audit CommitteeChen Weijun(Chairman)Wang RongliangChen Jinzhong Remuneration CommitteeWang Rongliang(Chairman)Jiang NianChen Jinzhong Nomination CommitteeJiang Nian(Chairman)Wang RongliangChen Jinzhong HONORARY CHAIRMANMao Yumin COMPANY SECRETARYPoon Hon Yin Clarendon House2 Church StreetHamilton HM 11, Bermuda REGISTERED OFFICEClarendon House2 Church StreetHamilton HM 11, Bermuda Corporate Information公司資料 PRINCIPAL PLACE OF BUSINESS INHONG KONG 145202002 Unit 2002, 20th floorOn Hong Commercial Building145 Hennessy RoadWan Chai, Hong Kong PRINCIPAL SHARE REGISTRAR ANDTRANSFER AGENT Conyers Corporate Services(Bermuda) LimitedClarendon House2 Church StreetHamilton HM 11, Bermuda Conyers Corporate Services(Bermuda) LimitedClarendon House2 Church StreetHamilton HM 11, Bermuda 1617 BRANCH SHARE REGISTRAR ANDTRANSFER AGENT IN HONG KONG Tricor Tengis Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong PRINCIPAL BANKERBank of Communications Co., Ltd. 399 STOCK CODE399 www.ipb.asiawww.irasia.com/listco/hk/ipb COMPANY WEBSITE www.ipb.asiawww.irasia.com/listco/hk/ipb Management Discussion and Analysis管理層討論及分析 GROUP RESULTS 3,000,0003,700,00018.9%101,700,000193,700,000 Revenue of the Group for the Financial Period amounted toapproximately HK$3.0 million, representing a decrease ofapproximately 18.9% as compared with the total revenueof approximately HK$3.7 million that was recorded inthe Previous Financial Period. The decrease was mainlyattributable to the decrease in business of the tradingof beauty equipment and products segment during theFinancial Period. The Group recorded a profit attributableto the owners of the Company amounted to approximatelyHK$101.7 million for the Financial Period as compared toprofit of HK$193.7 million in Previous Financial Period. Theprofit of both periods is attributable to the non-cash itemresult from the completion of the amendment of ConvertibleBonds II in the Financial Period and the third amendmentof Convertible Bonds III in the Previous Financial Period.The Convertible Bonds were restated to the fair value of theliability component at completion date of the ConvertibleBonds which was less than their carrying value. Thedifference of the carrying value and the fair value of theliability component was credited into income statements. BUSINESS REVIEW Trading of beauty equipment and products During the Financial Period, revenue arising from thetrading of beauty equipment and products amounted toapproximately HK$3.0 million, representing a decreaseof approximately 18.9% from the revenue in the amountof approximately HK$3.7 million that was recorded in thePrevious Financial Period. The trading business’s revenuecontinued to decline due to unfavourable business climate. 3,000,0003,700,00018.9% Research and development The in-process research and development project (the “In-process R&D”) represented an in-process research anddevelopment project involving an oral insulin product (the“Product”). The Group will inject additional resources intoclinical trial of the In-process R&D and consolidate the effortof the project team in order to facilitate the development ofit. The In-process R&D was recorded as intangible assetin Group’s consolidated statement of financial positionwith carrying value of HK$1,373 million. The managementperforms the impairment assessment at the end of eachreporting period. 1,373,000,000 Management Discussion and Analysis管理層討論及分析 At the end of the Financial Period, the Directors of theCompany have performed impairment assessment on theintangible asset. The recoverable amount of the intangibleasset is determined based on the estimated fair value of theIn-process R&D. Based on the assessment, the recoverableamount of the Group’s intangible asset is estimated tobe higher than the carrying amount and therefore theDirectors of the Company considered that no impairment isnecessary as at 30 September 2024. 480 The enrolment of the first batch of patients for the ClinicalTrial testing has commenced in July 2020. Currently, about480 patients have been enrolled in selected participatinghospitals to take place in the Clinical Trial. The enrolment ofpatient